SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03140761

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

The Prevalence of Secondary Adrenal Insufficiency in Patients With Exacerbation of COPD in Glucocorticoid Treatment Related to Differenct Gene Polymorphisms of the Glucocorticoid Receptor Gene

To investigate the correlation between four well-known polymorphisms of the glucocorticoid receptor gene (two with reduced sensitivity versus two with increased sensitivity) and the prevalence of secondary adrenal insufficiency in glucocorticoid-treated patients with exacerbation of COPD.

NCT03140761 Adrenal Insufficiency
MeSH: Adrenal Insufficiency
HPO: Adrenal insufficiency


Primary Outcomes

Description: test for adrenal function by stimulation test

Measure: Secondary Adrenal insufficiency

Time: average 1 month

Secondary Outcomes

Description: blood lipids, blood pressure, plasma glucose, abdominal obesity, body composition

Measure: Metabolic syndrome

Time: average 1 month

Description: bonemarkers

Measure: Bone mineral loss

Time: average 1 month

Measure: Onset of Diabetes Mellitus

Time: average 1 month

Description: test by questionnaires

Measure: Quality of life

Time: average 1 month

Time Perspective: Prospective

Case-Only


There is one SNP

SNPs


1 N363S

Inclusion Criteria: - Adult patients > 18 years - Caucasian classified with COPD - Patients with AECOPD being treated with at least 5 days of glucocorticoid (minimum of 180 mg) Exclusion Criteria: - Treated with estrogen-containing medications, including anticonceptiva 6 weeks prior to Synacthen® - Pregnancy or lactation - on regular systemic glucocorticoid therapy before admission to the hospital - People who are detained under the act on the use of coercion in psychiatry - Severe language problems or inability to provide written informed consent Inclusion Criteria: - Adult patients > 18 years - Caucasian classified with COPD - Patients with AECOPD being treated with at least 5 days of glucocorticoid (minimum of 180 mg) Exclusion Criteria: - Treated with estrogen-containing medications, including anticonceptiva 6 weeks prior to Synacthen® - Pregnancy or lactation - on regular systemic glucocorticoid therapy before admission to the hospital - People who are detained under the act on the use of coercion in psychiatry - Severe language problems or inability to provide written informed consent Adrenal Insufficiency Adrenal Insufficiency COPD patients who have received systemic glucocorticoid exceeding the equivalent of 180 mg prednisolone which are homo / heterozygous for the BclI and / or N363S polymorphisms (associated with increased glucocorticoid sensitivity) will have a lower cortisol response in a synacthen® test (greater suppression of adrenal corticosteroid) than the corresponding patients there are wild-type or homo- or heterozygous for the polymorphic ER22 / 23EK and / or 9β (associated with decreased sensitivity). --- N363S ---



HPO Nodes


HPO:
Adrenal insufficiency
Genes 136
SNRPN CYP11A1 SNORD116-1 VAMP7 NFKB2 PCSK1 TXNRD2 PEX1 SGPL1 IARS2 PEX14 BCOR HSD11B2 SOX9 SMARCB1 PEX2 TRNH HSD3B2 AIRE PEX10 CYP11B2 IPW GATA4 LHX4 NF2 PEX1 ND4 NPAP1 NNT PEX13 MCM4 TRNL1 CYP17A1 MKRN3 TXNRD2 LIPA ABCD1 PEX5 AAAS PEX12 PEX13 TCTN3 SRY TRNQ PCSK1 NR5A1 PEX19 TRNS2 AAAS RBM28 MAP3K1 PEX10 POMC HSD11B2 PEX6 CDH23 TRNS1 NR3C2 PEX3 PEX5 POR RBM28 PEX11B BRAF PWRN1 GK GLI3 MRAP SCNN1B AIRE CYP11A1 PEX14 ABCC8 PEX3 ZFPM2 NR0B1 NDN COX1 MAGEL2 SAA1 CDH23 MKRN3-AS1 STAR MRAP CTNNB1 TRNF PEX16 PEX19 PEX16 ND1 NR3C1 PWAR1 PEX12 TRNW COX3 CYP11B2 SAMD9 MEN1 CYP11B1 MC2R CYP11A1 PEX26 PEX2 WT1 NR0B1 PEX5 PEX6 GMPPA COX2 PDGFB DMRT3 PEX6 AIP TBX19 SNORD115-1 GLI3 MC2R POMC HBB SUFU KCNJ11 CYP11B2 ND6 PEX26 PEX11B TRAPPC11 MRPS7 STEAP3 ND5 PROP1 TBX19 HSD17B4 CYP11B1 HERC2 NFKB2 WWOX